CA-GLOBALLOGIC-INC.
GlobalLogic Inc. ,1 a Hitachi Group company and leader in Digital Engineering, today announced the availability of its enhanced Microservices Accelerator, a comprehensive and pluggable digital microservices development platform. Developed by GlobalLogic, this technology is used in conjunction with the company’s Digital Engineering services to greatly simplify and accelerate the design, configuration, and deployment of Microservices platforms – which are the most commonly deployed architectures in creating new digital experiences.
Notably, the Microservices Accelerator is currently the foundation platform for many GlobalLogic clients including EyeCare Partners , the leading healthcare service provider for optometry and ophthalmology; Petplan , the most comprehensive pet health care insurance in North America; and DISA Global Solutions , the leading provider of safety, compliance, and screening services.
Part of GlobalLogic’s Digital Accelerators product offerings, the Microservices Accelerator provides a complete solution that includes a project configurator and a set of pluggable modules that perform the most common Non-Functional Requirements (NFRs) required by any microservices-based deployment. The latest release introduces advanced capabilities including CloudEvents support, security framework upgrades, and ETag support to enhance caching capabilities.
Digital Accelerator Key Value Proposition
Driving the accelerator’s development were Independent Software Vendors (ISVs), enterprises, and startup company needs. As more companies move their product offerings to cloud-native platforms, developers seek codified tools that can efficiently address and automate common, time-consuming processes. Early results have shown a savings of up to 75 person months for a typical large-size deployment project, which means significantly reduced time to market, a more reliable and repeatable process, and increased ROI.
“Having deployed many such platforms over the last couple of years, GlobalLogic has established a strong body of knowledge that we have included in this toolset — ranging from enterprise-scale capabilities to best practices. Our clients are already shaving off months from the bootstrap, and reducing overall implementation costs and effort with our solution,” said Piyush Jha , SVP & Chief of Technology and Strategy (APAC), GlobalLogic.
“Microservices is a great architectural paradigm that takes modularity to the next level and, in many ways, is fundamental for achieving the massive scale requirements of modern software,” said Deepak Gupta , SVP & Global Head of Technology Practices, GlobalLogic. “This accelerator is an out-of-box solution that allows engineers to set up complex architectures in a single day, rather than the months typically required. Moreover, it provides a required guardrail to operate within, and reduces the possibilities of human error — which is essential to being successful with this programming paradigm.”
Inter-Company Deployment
As part of Hitachi’s acquisition of GlobalLogic, the accelerator technology will be utilized in Hitachi's services and solutions going forward.
“Hitachi Application Services Division is excited to leverage the GlobalLogic Accelerators in its service delivery schema,” said Emi Goto, Senior Director, Application Services Division, Hitachi, Ltd. “The growth of our Lumada business will be accelerated in the expanding Digital Transformation market by combining the innovativeness of GlobalLogic's Experience Design and Chip-to-Cloud software engineering with Hitachi's enterprise application delivery experiences in mission critical systems.”
GlobalLogic’s Microservices Accelerator supports both containers and functions as a service-based deployment model across cloud hyperscalers Microsoft Azure, AWS, and Google Cloud Platform (GCP).
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
1 July 14, 2021 News Release "Hitachi Completes Acquisition of GlobalLogic” https://www.hitachi.com/New/cnews/month/2021/07/f_210714.pdf
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005358/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom